For the second time since August, the FDA has approved a new treatment for a rare and deadly disease called hereditary transthyretin amyloidosis (hATTR). The agency’s nod for inotersen (Tegsedi) sets the sage for a market battle between the drug’s developer, Akcea Therapeutics, and rival Alnylam Pharmaceuticals. The FDA approved inotersen for treating polyneuropathy, the […]
Original Article: FDA OKs Akcea Rare Disease Drug, Setting Up Market Clash with Alnylam